Kallyope
Kallyope is a New York City biotechnology company developing medicines from neural signaling insights.
Founded
2015Kallyope is a New York City biotechnology company developing medicines from neural signaling insights.
Kallyope pairs a differentiated neural circuits discovery platform with clinical-stage assets, giving it both a target engine and near-term value drivers in elismetrep and K-554. Elismetrep offers a non-triptan oral mechanism for acute migraine, a large market where patients still need alternatives to existing therapies, and K-554 pursues obesity through a non-incretin weekly injectable that could differentiate from the incretin class.
The company is backed by founders from Columbia University and the Howard Hughes Medical Institute alongside experienced biotech leadership, and it has raised substantial venture capital including a 236 million dollar Series D. A licensing relationship with Novo on early-stage obesity programs provides external validation of the platform while Kallyope retains its lead migraine and metabolic candidates.
Source: kallyope.com
Kallyope competes in two large and active therapeutic markets: acute migraine, where oral alternatives to triptans continue to gain share, and obesity and metabolic disease, where demand for effective weight-loss medicines far exceeds supply. Positive Phase 2b data for elismetrep positions the company to enter a migraine market that rewards differentiated mechanisms with stronger efficacy or tolerability.
In metabolism, the success of incretin medicines has drawn heavy investment while leaving room for non-incretin approaches with different tolerability or dosing profiles. Kallyope advances K-554 in this context while its Novo-licensed programs show that large pharmaceutical companies value its early obesity pipeline, though clinical and competitive risks remain typical of mid-stage biotech.
Kallyope is a New York biotechnology company developing therapeutics that target neural circuits connecting the gut and the brain. Its lead program is elismetrep, an oral selective TRPM8 channel blocker for the acute treatment of migraine that reported positive Phase 2b results and is advancing toward Phase 3 development.
The pipeline also includes K-554, a once-weekly injectable non-incretin peptide for obesity and metabolic disease in Phase 1 studies. Kallyope presents its discovery engine as a neural circuits platform that maps gut-brain signaling to identify drug targets across migraine and metabolism.
Source: kallyope.com
Source: kallyope.com